SenseTime 20 HK
Sector : Tech - Application Software
Specialty : Artificial intelligence products
The stocks is stirred by news of Goldman backing up Chinese Biotech MegaRobo Tech to raise about $300 mio funding amid global tech sector rout. MegaRobo applies roboticsand AI towards life science research, deepen forays into fields from stem cell therapy togenetics to traditional Chinese medicine. The investment highlight how innovative technology can still attract capital.
Revenue
4.70 bio(2021), 6.23 bio (2022)
Gross Margin
70.57 (2020), 69.73 (2021) 69.52 (2022)
Sudden increase of volume trend could be positive for trading towards $6.75/85 target (10% upside)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
d